Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Oncology drugs
Fierce Pharma
Daiichi Sankyo targets global top 5 oncology rank by 2035
By 2030, Daiichi envisions its revenues will reach more than 3 trillion yen ($19.1 billion), with 2.3 trillion yen from its oncology portfolio.
Angus Liu
May 11, 2026 10:22am
How Jeff Legos builds Pfizer’s oncology future
Mar 4, 2026 2:00pm
Cullinan puts kibosh on 2 cancer assets amid autoimmune refocus
Nov 6, 2025 1:26pm
Karyopharm lays off 20% of staffers amid hunt for alternatives
Jul 11, 2025 11:02am
TegMine bags tech from OBI to help fuel ADC ambitions
Jun 6, 2025 10:00am
Ascletis slashes funds for former core programs in obesity pivot
Mar 26, 2025 10:00am